Jun 2, 2025, 08:50

Biology of Bladder Cancer (R01 Clinical Trial Optional)

R01 research grants supporting comprehensive studies on the molecular and cellular mechanisms of bladder cancer initiation, progression, recurrence, and microenvironmental interactions. Clinical trials (particularly early‐phase NMIBC interception) are allowed if they complement a strong mechanistic focus. Applications must be grounded in substantial preliminary data or established proof‐of‐principle.

Eligibility

Eligible entities (U.S. & foreign): Higher education institutions; nonprofits; for‐profits (including small businesses); state/local governments; tribal organizations; faith‐based/community organizations; regional organizations; non‐U.S. entities.
Investigators: Any qualified PD/PI(s) with eRA Commons account(s). Teams are encouraged to include co‐investigators with expertise outside bladder cancer (e.g., metabolism, immunology, engineering).
Project types: R01 mechanism. Clinical trials permitted but must support mechanistic aims; translational/economic aims are acceptable only when tied to biological objectives.

Funding

Mechanism: R01 Research Project Grant (clinical trial optional)
Direct costs: No set cap; budgets must reflect actual project needs
Project period: Up to 5 years
Number of awards: Dependent on NIH appropriations and application quality

Key Dates

Letter of Intent: 30 days before application due date
Application due (standard NIH dates):
- February 05, 2025, 5 PM local time
- June 05, 2025, 5 PM local time
Review & Council:
- July 2025 → Advisory Council October 2025 → Earliest start December 2025 (Feb cycle)
- November 2025 → Advisory Council January 2026 → Earliest start April 2026 (June cycle)
Expiration: September 08, 2025

Contacts

Programmatic Queries (Cancer Biology):
- Ron Johnson, Ph.D. | 240-276-6250 | [email protected]
- Elisa Woodhouse, Ph.D. | 240-276-6220 | [email protected]
Programmatic Queries (Prevention/Epidemiology):
- Howard L. Parnes, M.D. (Prevention) | [email protected]
- Tram Kim Lam, Ph.D., M.P.H. (Epidemiology) | [email protected]
GrantsInfo: [email protected] | 301-480-7075
Grants.gov Support: [email protected] | 800-518-4726

bladder cancer disparities experimental models field cancerization metabolism MIBC microbiome Molecular Mechanisms NMIBC progression R01 recurrence Tumor biology tumor microenvironment

FDA has Granted Full Market Approval for Papzimeos - NIH

Kirsty Duncan։ Thirty-two Months Into Fighting Cancer...

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer